title: Expression and clinical significance of microRNA-152 in supragalottic laryngeal carcinoma.
abstract: MicroRNAs (miRNAs) are small, noncoding RNAs of endogenous origin that play an important role in tumor development. Here, we examined the role of miR-152 in supragalottic laryngeal carcinoma. The expression of miR-152 was assessed by real-time PCR in tissues from 83 patients with supragalottic laryngeal carcinoma in relation to clinicopathological parameters. Cell viability was assessed by thiazolyl blue assay in Hep-2 cells transfected with miR-152 mimics or a negative control. MiR-152 was significantly downregulated in supragalottic laryngeal carcinoma tissues (t = 12.65, p < 0.001, paired t test), and its expression was correlated with pT stage (χ(2) = 26.88, p < 0.001) and pN stage (z = -3.56, p < 0.001) in patients with supragalottic laryngeal carcinoma. MiR-152 inhibited the proliferation of Hep-2 cells. MiR-152 may serve as a novel prognostic marker in patients with supragalottic laryngeal carcinoma.
authors.affiliation: Department of Otorhinolaryngology, The Shengjing Hospital, China Medical University, Shenyang, 110004, Liaoning Province, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Song
authors.forename: Yuan
authors.initials: Y
authors.lastname: Tian
authors.forename: Wei-Liang
authors.initials: WL
authors.lastname: Bai
authors.forename: Xiu-Lan
authors.initials: XL
authors.lastname: Ma
mesh_terms: D000368:Aged; D049109:Cell Proliferation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007822:Laryngeal Neoplasms / Q000235:genetics* / Q000473:pathology*; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D009367:Neoplasm Staging; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured
chemical_list: C550856:MIRN152 microRNA, human; D035683:MicroRNAs; D012333:RNA, Messenger
references.citation: BMJ. 2002 Oct 12;325(7368):822-7
references.pmid: 12376446
references.citation: Nat Med. 1998 Mar;4(3):328-32
references.pmid: 9500607
references.citation: PLoS One. 2014 Jan 09;9(1):e81730
references.pmid: 24416131
references.citation: Biotechniques. 2005 Oct;39(4):519-25
references.pmid: 16235564
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: J Physiol Biochem. 2011 Mar;67(1):129-39
references.pmid: 20981514
references.citation: Biochem Biophys Res Commun. 2013 Aug 16;438(1):48-53
references.pmid: 23867826
references.citation: Oncotarget. 2014 Jun 15;5(11):3512-25
references.pmid: 25004396
references.citation: Cancer Lett. 2013 Feb 28;329(2):146-54
references.pmid: 23142217
references.citation: FEBS Lett. 2014 May 21;588(10):1983-8
references.pmid: 24780186
references.citation: Cancer Biol Ther. 2014 Apr;15(4):419-27
references.pmid: 24448385
references.citation: Arch Med Res. 2010 Feb;41(2):67-74
references.pmid: 20470934
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: Nat Rev Cancer. 2006 Nov;6(11):857-66
references.pmid: 17060945
references.citation: Tumour Biol. 2014 Aug;35(8):7713-7
references.pmid: 24805828
references.citation: Prostate. 2013 Jul;73(10):1082-9
references.pmid: 23460133
references.citation: Oncogene. 2014 Jan 16;33(3):378-86
references.pmid: 23318422
references.citation: Silence. 2010 Feb 02;1(1):6
references.pmid: 20226080
references.citation: Mol Cancer. 2012 Aug 21;11:58
references.pmid: 22909061
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609